S64
29.9.2022 14:40:15 CEST | Business Wire | Press release
S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020.
S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs.
Strategic hires following rapid growth
Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deutsche Bank; Mark Slater, Legal Counsel and Compliance, formerly of J.P. Morgan and Simmons & Simmons; and Eve Wachtel, Asia Pacific Distribution, formerly of Deutsche Bank.
The firm’s structuring and solutions team also boasts three new additions, comprising Matteo De Checchi, Dennis Bews and Adam Hooper, from Deutsche Bank, Credit Suisse and Barings respectively.
S64 expects to more than double its 40-strong headcount over the next 12 months across its structuring, distribution, platform and technology expertise.
Tarun Nagpal, CEO of S64, commented: “I’m delighted to welcome some of the industry’s leading talent to our firm. Not only do they bring with them deep technical experience, but a track record of market-defining innovation.
We are witnessing a revolution in how private markets are accessed. Our award-winning legacy, unique proposition and market-leading expertise mean we are well-positioned to build upon our impressive growth to date.
As we define a new era in alternative assets, we plan to deepen our expertise through further strategic hires and expand our presence into target markets over the coming year.”
Pipeline of mandates with platinum-level clients
S64 is already the trusted partner of global leaders across private equity, asset management and private wealth having won numerous competitive mandates, including the majority of the top 10 largest private markets managers globally, who have raised over $750 billion USD of funds in the past decade. The firm has built market share at speed with a robust pipeline of new opportunities.
The business is leading the way in industry innovation through the development of an array of novel solutions for clients, including the structuring, delivery and servicing of ELTIFs, UK LTAFs, and open-ended semi-liquid retail products, helping them rapidly scale their offerings.
Tarun Nagpal added: “We’re excited to be working with platinum-level asset managers and private banks, having won a pipeline of highly-coveted mandates which has turbocharged our ambitious growth trajectory.
With our world-class proprietary technology, which services the full lifecycle of alternatives products, our innovative approach is further opening up access to private markets and enabling them to flourish.”
ENDS.
Notes to Editors
- Global fund manager ranking and fundraising amount according to Preqin’s Fund Managers League Table as of 25.09.22.
- Preqin calculates top global fund managers based on aggregate capital raised via closed-end commingled funds.
- Fundraising amount is based on funds raised in the last 10 years.
About S64
S64 is a leading global alternatives solutions business bridging the opportunity in private markets. It works with the world’s first-class asset managers and private banks across private equity, credit, real estate, infrastructure and impact to develop innovative solutions for private banks and wealth managers.
S64’s innovative technology platform offers the full lifecycle management of alternative assets — from structuring and onboarding to financing, as well as secondary market capabilities.
Its team draws on an award-winning legacy in fund and product solutions, digital innovation and international distribution, having pioneered alternative investment platforms for over a decade.
www.s64capital.com | LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom